

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60790	INTERNATIONAL APPLICATION NO. PCT/US2004/008026
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Busch-Petersen et al.	
		FILING DATE Herewith Sept. 14, 2006	GROUP 1624

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
/B.C./	U.S. 6,605,607 B1	12-Aug-2003	HADLEY et al.	514	217.01	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/B.C./	AUSTIN et al, Novel 2,3,4,5-Tetrahydro-1H-3-benzazepinewith High Affinity and Selectivity for the Dopamine D.sub.3 Receptor, Bioorganic & Medicinal Chemistry Letters, 20 November 2000, Vol. 10, No. 22, pages 2553-2555, especially pages 2554 and 2555.		
/B.C./	MACDONALD et al., Design and Synthesis of trans-3-(2,44-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))-phenyl)carbomido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D.sub.3 Receptor Antagonist, Journal of Medicinal Chemistry, 06 November 2003, Vol. 46, No. 23, pages 4952-4964, especially pages 4956 and 4957.		
EXAMINER	/Brenda Coleman/	DATE CONSIDERED	09/28/2008
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			